15-12G - Class Acceleration Corp. (0001826855) (Filer)

25-NSE - Class Acceleration Corp. (0001826855) (Subject)

8-K - Class Acceleration Corp. (0001826855) (Filer)

DEF 14A - Class Acceleration Corp. (0001826855) (Filer)

PRE 14A - Class Acceleration Corp. (0001826855) (Filer)

NT 10-Q - Class Acceleration Corp. (0001826855) (Filer)

8-K - Class Acceleration Corp. (0001826855) (Filer)

10-Q - Class Acceleration Corp. (0001826855) (Filer)

10-K - Class Acceleration Corp. (0001826855) (Filer)

10-Q - Class Acceleration Corp. (0001826855) (Filer)

WOODSIDE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- On December 20, 2022, the stockholders of Class Acceleration Corp. (the "Company") approved (i) an amendment to the Company's second amended and restated certificate of incorporation (the "Charter") to extend the date by which the Company would be required to consummate a business combination from January 20, 2023 to June 20, 2023 (the "Extension Amendment"), (ii) an amendment to the Charter to permit the Company's Board, in its sole discretion, to elect to wind up the Company's operations on an earlier date (the "Liquidation Amendment" and, together with the Extension Amendment, the "Charter Amendments"), (iii) an amendment to the Compan

WOODSIDE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Class Acceleration Corp. (NYSE:CLAS, CLAS.U, CLAS.W))) (the "Company") today announced that it filed a Proxy Statement with the Securities and Exchange Commission (the "SEC") on December 6, 2022 with several proposals, including a request to extend the date by which the Company would be required to consummate a business combination from January 20, 2023 to June 20, 2023. Class Acceleration Corp.'s Board of Directors asks shareholders to vote FOR proposal 1 prior to the Company's 2022 meeting of stockholders on December 20, 2022. Michael Moe, Class Acceleration Corp.'s Chief Executive Officer stated, "There are immediate and actionable op

WOODSIDE, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Class Acceleration Corp. (NYSE:CLAS, CLAS.U, CLAS.W))) (the "Company") today announced that it received a notice from the New York Stock Exchange (the "NYSE") indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the "Q3 2021 Form 10-Q") with the Securities and Exchange Commission (the "SEC"). The notice has no immediate effect on the listing of the Company's stock on the NYSE. The NYSE informed the Company that, under the NYSE's rules, the Company can regain compliance

SAN FRANCISCO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSXV:CLAS, OTC:CLAS) (the "Company" or "Claritas") today announced the engagement of B. Riley Securities, Inc. ("B. Riley Securities") as its exclusive capital markets advisor with respect to the Company's planned up-listing of its securities on the OTCQB. "We view the planned up-listing on the OTCQB as an important milestone for Claritas," stated Robert Farrell, Claritas' President and CEO. "The OTCQB will afford us greater visibility within the U.S. investment community, should enhance our liquidity and should increase our access to U.S. institutional and retail investors. We believe this ad

SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSXV:CLAS, OTC:CLAS) (the "Company" or "Claritas") is pleased to announce that it has closed the first tranche of a private placement offering (the "Offering") of convertible debentures with Obsidian Global GP, LLC ("Obsidian") for net proceeds of USD $930,000. Highlights Claritas received aggregate proceeds of approximately CAD $1,247,000 (the "Aggregate Proceeds") from the closing. Subject to the satisfaction of certain equity conditions, entry into the relevant agreements between the parties, and TSXV approval, a second tranche of the Offering may close in 90 days to provide additional proceeds of USD $75

SAN FRANCISCO and TORONTO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSXV:CLAS, OTC:CLAS) (the "Company" or "Claritas") today announced that it has entered into a binding Letter of Intent (the "LOI") with Biozeus Biopharmaceuticals S. A., a Brazilian corporation ("Biozeus"), under which Biozeus will grant to Claritas an option to acquire an exclusive, worldwide license to develop and commercialize Biozeus' novel, proprietary drug, BZ371B, for the prevention and treatment of pulmonary diseases, including ARDS and asthma (the "Option"). The Company's entry into the Option is subject to receipt of all regulatory approvals, including approval of the TSX Venture Exchang

SC 13G/A - Class Acceleration Corp. (0001826855) (Subject)

SC 13G/A - Class Acceleration Corp. (0001826855) (Subject)

SC 13G - Class Acceleration Corp. (0001826855) (Subject)

SC 13G - Class Acceleration Corp. (0001826855) (Subject)

SC 13G/A - Class Acceleration Corp. (0001826855) (Subject)

SC 13G - Class Acceleration Corp. (0001826855) (Subject)